Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.

NCT03549000 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT03549000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03549000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
July 18, 2018
Completion date
October 17, 2022
Enrollment
127 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer microsatellite stable (mss), metastatic castration resistant prostate cancer (mcrpc), non-small cell lung cancer (nsclc), ovarian cancer, pancreatic ductal adenocarcinoma (pdac), renal cell carcinoma (rcc), triple negative breast cancer (tnbc)